Sam Altman, CEO of OpenAI, is focusing on Retro Biosciences, a San Francisco-based biotech startup that aims to help humans live 10 years longer than the so-called healthy lifespan. I want it.
Altman previously provided Retro Bioscience's entire seed round of $180 million. The startup has now raised $1 billion in Series A funding, with Altman also participating, the Financial Times reports.
Retro Biosciences, which plans to begin clinical trials for treatments for diseases such as Alzheimer's disease, recently used OpenAI to train a model to turn ordinary cells into stem cells.
CEO Joe Betts-LaCroix told the FT that he wants to discover and develop new drugs and move quickly “in the 2020s.”
The startup is joined by other billionaire-backed companies, including Altos Labs, which was founded with $3 billion in 2022 and is backed by Jeff Bezos, and Unity Biotechnology, which is backed by both Bezos and Peter Thiel. joins major longevity initiatives.